9625 West 76th Street
Minneapolis, MN 55344
Hysitron Joins Bruker Nano Surfaces Division
Bruker Announces Acquisition of Nanoindenting Leader Hysitron
Acquisition strengthens Bruker’s leading position in nanoanalysis and nanomechanical materials characterization
BILLERICA, Massachusetts ─ January 24, 2017 ─ Bruker today announced that it has acquired Hysitron, Inc., a technology leader in the development, manufacture, and sale of nanomechanical test instrumentation. The acquisition adds Hysitron’s innovative nanomechanical testing instruments to Bruker’s existing portfolio of atomic force microscopes (AFMs), surface profilometers, and tribology and mechanical testing systems, significantly enhancing Bruker’s leadership position in nanomaterials research markets. Hysitron’s 2016 revenues were approximately $20 million. Financial details of the transaction were not disclosed.
Headquartered in Eden Prairie, Minnesota, privately-held Hysitron® has pioneered solutions to measure mechanical properties of materials at the nanoscale since 1992. Its industry-leading nanoindentation products are used by premier academic and industrial researchers and engineers in materials science, the life sciences, and semiconductor applications. In addition to nanoindentation and microindentation, Hysitron's instrument capabilities include tribology, modulus mapping, dynamic mechanical analysis, and in-situ SEM (scanning electron) and TEM (transmission electron) nanomechanical testing.
“Hysitron has been recognized as the global market and technology leader in the field of nanomechanical property measurements for quite some time,” said Mark R. Munch, Ph.D., President of the Bruker NANO Group. “As a leader in atomic force microscopy instrumentation, we plan to realize a number of valuable application synergies by adding Hysitron’s instruments to our Bruker NANO Group nanoscale surface and materials characterization product portfolio. In addition, Hysitron’s products are quite complementary to our macroscale mechanical and tribology test instruments, providing the most complete range of testing capabilities to the market.”
“We have built a strong reputation at Hysitron for truly top-level instrumentation that pushes the limits of nanoindenting technology, but have been looking to leverage the strengths of a larger global organization to help bring these capabilities to their full potential,” added Thomas Wyrobek, CEO and Co-Founder of Hysitron, Inc. “With Bruker’s great commitment to research and their long history of academic collaboration, we are excited about the ways they can provide the global infrastructure and processes that we have always wanted, while maintaining intense focus on developing the best possible solutions to enable our customers’ success.”
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect. Our actual future performance may differ materially from such expectations as a result of important risk factors, which include, in addition to those identified in our Annual Report on Form 10-K for the year ended December 31, 2015 and our other subsequent filings with the Securities and Exchange Commission, risks and uncertainties associated with our ability to finalize and close, and then manage and integrate the acquisition of Hysitron, Inc. These risks and uncertainties could cause actual results to differ materially from those stated or implied in these forward-looking statements. We expressly disclaim any obligation to update or revise these forward-looking statements, except as required by law or regulation.
About Hysitron, Inc.
Hysitron is the world leader in the development and commercialization of nanomechanical test instruments and has designed, manufactured, and serviced cutting-edge technology for the scientific community since 1992. As the pioneer of in-situ imaging with nanomechanical property measurement capabilities, Hysitron has grown with the nanotechnology market for over two decades.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Bruker Head of Investor Relations
T: +1 (978) 663-3660 x1479
Bruker Nano Surfaces MarCom Supervisor
T: +1 (520) 741-1044 x1022